Cesarean births are not likely linked to an elevated risk of food allergy during the first year of life, an Australian study found. Published online in the Journal of Allergy and Clinical Immunology, the findings may help assess the risks and benefits of cesarean delivery and reassure women who require it that their babies are not more likely to develop food allergy, according to Rachel L. Peters, PhD, an epidemiologist at the Murdoch Child Research Institute (MCRI) in Melbourne, and colleagues.
Latest posts made by Dennis james
Food Allergy Risk Not Greater in C-Section Infants
Analysis Shows Predictive Capabilities of Sleep EEG
Overnight sleep electroencephalography (EEG) contains an abundance of brain wave data that could be mined to identify an individual's risk for a host of health outcomes, including dementia, cognitive impairment, and cardiovascular events. The results suggest that it's feasible to use sleep to identify people with high risk of unfavorable outcomes and it strengthens the concept of sleep as a window into brain and general health
RE: Testing Sperm at Home: The Latest Infertility Trend
@anjali-1 Most home sperm tests are basic measures of sperm count (and in some cases, sperm motility) but give no information on sperm morphology or other biochemical characteristics. Several home-based tests to date have been approved by the US Food and Drug Administration. Some are single-use test kits containing the supplies to collect semen, prepare it, and transfer it to a test strip. Others are smartphone-based technologies that include microscopes that work in tandem with a phone or tablet's camera. Costs range from about $25 to $90.
RE: Spinal Cord Stimulation Durable for Painful Diabetic Neuropathy
@md-aslam New 18-month data for a 10-kHz implanted spinal cord stimulation device (Nevro) shows continued relief of painful diabetic neuropathy symptoms in patients refractory to conventional medical therapy.
The 10-kHz device, called HFX, involves minimally invasive epidural implantation of the stimulator device, which delivers mild electrical impulses to the nerves to interrupt pain signals to the brain. It was approved by the US Food and Drug Administration (FDA) in July 2021 based on 6-month efficacy and safety data and is currently the only spinal cord stimulation system approved by the FDA specifically with an indication for painful diabetic neuropathy.
The 18-month data from the randomized SENZA-PDN trial were presented May 14, at the American Association of Clinical Endocrinology (AACE) 2022 annual meeting by Christian Nasr, MD, an endocrinologist at the Cleveland Clinic, Ohio.
The 18-month time period, following publication of the 12-month data, now exceeds the duration of trials for most medications used to treat painful diabetic neuropathy.
The findings confirm this is a viable method of helping patients with painful diabetic neuropathy, and it's durable.
We see a lot of these patients not being controlled with oral medications. It really impacts their quality of life. This is adding to the options we can offer them for pain control.
Typically, the medications we prescribe don't relieve pain as fast. So, I think this is a plus...They were able to tolerate it well and the pain control was sustained."
However, the cost may be an issue for many (although it is covered by most insurance plans, according to the Nevro website).